Study #2020-0507
A Randomized, Controlled, Open-label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination with RP1 in Patients with Advanced Cutaneous Squamous Cell Carcinoma
MD Anderson Study Status
Not Accepting
Treatment Agent
Cemiplimab, RP1
Description
To estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with RP1 for patients with locally advanced or metastatic CSCC, as assessed by overall response rate (ORR) and complete response rate (CRR) according to blinded independent review.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
Study phase:
Phase II
Physician name:
Michael Migden
Department:
Dermatology
For general questions about clinical trials:
1-844-338-0349
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.